Does the media prefer VKTX or MDGL?

In the previous week, Viking Therapeutics had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 10 mentions for Viking Therapeutics and 5 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.11 beat Viking Therapeutics' score of 0.56 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VKTX or LLY?

In the previous week, Eli Lilly and Company had 155 more articles in the media than Viking Therapeutics. MarketBeat recorded 165 mentions for Eli Lilly and Company and 10 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.99 beat Viking Therapeutics' score of 0.56 indicating that Eli Lilly and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Eli Lilly and Company 99 Very Positive mention(s) 22 Positive mention(s) 30 Neutral mention(s) 9 Negative mention(s) 4 Very Negative mention(s) Positive

Does the media prefer PFE or VKTX?

In the previous week, Pfizer had 62 more articles in the media than Viking Therapeutics. MarketBeat recorded 72 mentions for Pfizer and 10 mentions for Viking Therapeutics. Pfizer's average media sentiment score of 0.78 beat Viking Therapeutics' score of 0.56 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 36 Very Positive mention(s) 18 Positive mention(s) 8 Neutral mention(s) 6 Negative mention(s) 4 Very Negative mention(s) Positive Viking Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBIO or VKTX?

In the previous week, BridgeBio Pharma had 9 more articles in the media than Viking Therapeutics. MarketBeat recorded 19 mentions for BridgeBio Pharma and 10 mentions for Viking Therapeutics. BridgeBio Pharma's average media sentiment score of 0.62 beat Viking Therapeutics' score of 0.56 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, VKTX or SMMT?

Summit Therapeutics is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A

Is VKTX or SMMT more profitable?

Viking Therapeutics' return on equity of -71.31% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -71.31% -65.35% Summit Therapeutics N/A -291.24% -243.07%

Does the media favor VKTX or SMMT?

In the previous week, Viking Therapeutics had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 10 mentions for Viking Therapeutics and 4 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.04 beat Viking Therapeutics' score of 0.56 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viking Therapeutics (VKTX) Competitors

$32.74 +0.55 (+1.71%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$32.72 -0.02 (-0.08%)

As of 05/29/2026 07:55 PM Eastern

Compare

VKTX vs. MDGL, LLY, PFE, BBIO, and SMMT

Should you buy Viking Therapeutics stock or one of its competitors? MarketBeat compares Viking Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Pfizer (PFE), BridgeBio Pharma (BBIO), and Summit Therapeutics (SMMT). These companies are all part of the "medical" sector.

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viking Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its share price is 204% less volatile than the broader market.

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Madrigal Pharmaceuticals' return on equity of -50.15% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%

In the previous week, Viking Therapeutics had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 10 mentions for Viking Therapeutics and 5 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.11 beat Viking Therapeutics' score of 0.56 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Madrigal Pharmaceuticals	$958.40M	11.96	-$288.28M	-$12.80	N/A

Viking Therapeutics currently has a consensus price target of $93.60, suggesting a potential upside of 185.89%. Madrigal Pharmaceuticals has a consensus price target of $687.00, suggesting a potential upside of 38.15%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76

Summary

Viking Therapeutics and Madrigal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Eli Lilly and Company?

Viking Therapeutics (NASDAQ:VKTX) and Eli Lilly and Company (NYSE:LLY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Eli Lilly and Company has a net margin of 34.98% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 105.77% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Eli Lilly and Company	34.98%	105.77%	23.76%

Viking Therapeutics presently has a consensus target price of $93.60, suggesting a potential upside of 185.89%. Eli Lilly and Company has a consensus target price of $1,227.00, suggesting a potential upside of 11.00%. Given Viking Therapeutics' higher probable upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

In the previous week, Eli Lilly and Company had 155 more articles in the media than Viking Therapeutics. MarketBeat recorded 165 mentions for Eli Lilly and Company and 10 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.99 beat Viking Therapeutics' score of 0.56 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Eli Lilly and Company	99 Very Positive mention(s)	22 Positive mention(s)	30 Neutral mention(s)	9 Negative mention(s)	4 Very Negative mention(s)	Positive

Viking Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Eli Lilly and Company	$72.25B	14.41	$20.64B	$28.15	39.27

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to Pfizer?

Pfizer (NYSE:PFE) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Pfizer has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.31B	2.36	$7.77B	$1.31	19.99
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Pfizer currently has a consensus price target of $28.82, suggesting a potential upside of 10.08%. Viking Therapeutics has a consensus price target of $93.60, suggesting a potential upside of 185.89%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.20
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Pfizer has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pfizer has a net margin of 11.83% compared to Viking Therapeutics' net margin of 0.00%. Pfizer's return on equity of 19.44% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Viking Therapeutics	N/A	-71.31%	-65.35%

In the previous week, Pfizer had 62 more articles in the media than Viking Therapeutics. MarketBeat recorded 72 mentions for Pfizer and 10 mentions for Viking Therapeutics. Pfizer's average media sentiment score of 0.78 beat Viking Therapeutics' score of 0.56 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	36 Very Positive mention(s)	18 Positive mention(s)	8 Neutral mention(s)	6 Negative mention(s)	4 Very Negative mention(s)	Positive
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pfizer beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Viking Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Viking Therapeutics	N/A	-71.31%	-65.35%

BridgeBio Pharma has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 9 more articles in the media than Viking Therapeutics. MarketBeat recorded 19 mentions for BridgeBio Pharma and 10 mentions for Viking Therapeutics. BridgeBio Pharma's average media sentiment score of 0.62 beat Viking Therapeutics' score of 0.56 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma presently has a consensus target price of $88.90, suggesting a potential upside of 34.18%. Viking Therapeutics has a consensus target price of $93.60, suggesting a potential upside of 185.89%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Viking Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.85	-$724.93M	-$3.74	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Summary

BridgeBio Pharma beats Viking Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Summit Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Viking Therapeutics presently has a consensus price target of $93.60, indicating a potential upside of 185.89%. Summit Therapeutics has a consensus price target of $26.05, indicating a potential upside of 48.54%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.35

Viking Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.25, suggesting that its share price is 225% less volatile than the broader market.

Viking Therapeutics' return on equity of -71.31% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Viking Therapeutics had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 10 mentions for Viking Therapeutics and 4 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.04 beat Viking Therapeutics' score of 0.56 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Viking Therapeutics beats Summit Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VKTX vs. The Competition

Export

Metric	Viking Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.80B	$3.41B	$5.96B	$12.56B
Dividend Yield	N/A	2.29%	2.69%	5.31%
P/E Ratio	-7.91	18.88	21.63	26.27
Price / Sales	N/A	342.04	626.55	142.41
Price / Cash	N/A	121.88	43.22	56.84
Price / Book	7.58	7.12	10.55	7.30
Net Income	-$359.64M	$24.20M	$3.56B	$337.27M
7 Day Performance	5.99%	4.11%	2.85%	3.58%
1 Month Performance	5.00%	6.66%	4.59%	5.71%
1 Year Performance	21.35%	66.00%	37.62%	39.70%

Viking Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VKTX Viking Therapeutics	3.7341 of 5 stars	$32.74 +1.7%	$93.60 +185.9%	+21.3%	$3.80B	N/A	N/A	20	Analyst Forecast
MDGL Madrigal Pharmaceuticals	2.721 of 5 stars	$513.47 +0.3%	$687.00 +33.8%	+79.7%	$11.80B	$958.40M	N/A	90	Positive News
LLY Eli Lilly and Company	4.5262 of 5 stars	$1,016.05 -0.5%	$1,218.33 +19.9%	+49.7%	$961.90B	$65.18B	36.09	50,000	Trending News Analyst Forecast Options Volume
PFE Pfizer	3.6824 of 5 stars	$25.78 +0.5%	$28.61 +11.0%	+11.6%	$146.25B	$62.58B	19.68	75,000	Trending News Analyst Forecast
BBIO BridgeBio Pharma	3.4768 of 5 stars	$68.22 +3.4%	$88.90 +30.3%	+92.7%	$12.93B	$502.08M	N/A	400	Analyst Downgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VKTX) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, BBIO, and SMMT

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Summary

How does Viking Therapeutics compare to Pfizer?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Summary

How does Viking Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, BBIO, and SMMT

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Do insiders & institutionals hold more shares of VKTX or MDGL?

Which has more volatility and risk, VKTX or MDGL?

Is VKTX or MDGL more profitable?

Does the media prefer VKTX or MDGL?

Which has preferable valuation & earnings, VKTX or MDGL?

Do analysts prefer VKTX or MDGL?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Is VKTX or LLY more profitable?

Do analysts prefer VKTX or LLY?

Does the media favor VKTX or LLY?

Which has more volatility & risk, VKTX or LLY?

Which has higher valuation & earnings, VKTX or LLY?

Do insiders and institutionals have more ownership in VKTX or LLY?

Summary

How does Viking Therapeutics compare to Pfizer?

Which has better valuation and earnings, PFE or VKTX?

Do analysts prefer PFE or VKTX?

Which has more risk and volatility, PFE or VKTX?

Do institutionals & insiders hold more shares of PFE or VKTX?

Is PFE or VKTX more profitable?

Does the media prefer PFE or VKTX?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Do institutionals and insiders hold more shares of BBIO or VKTX?

Is BBIO or VKTX more profitable?

Which has more volatility and risk, BBIO or VKTX?

Does the media prefer BBIO or VKTX?

Do analysts prefer BBIO or VKTX?

Which has higher earnings & valuation, BBIO or VKTX?

Summary

How does Viking Therapeutics compare to Summit Therapeutics?

Do analysts recommend VKTX or SMMT?

Which has more risk and volatility, VKTX or SMMT?

Is VKTX or SMMT more profitable?

Does the media favor VKTX or SMMT?

Which has stronger earnings & valuation, VKTX or SMMT?

Do insiders and institutionals believe in VKTX or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools